Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART).
Cellectis' goal is to create innovative products in multiple fields and with various target markets.
Cellectis was founded in 1999 by Andra Choulika and is headquartered in Paris, with an office in New York City.
Cellectis has raised a total of $17.4M in 3 funding rounds. The company received their last funding on Jun 1, 2005, where they cashed $5.6M from 4 investors in a "Series C" funding. The company went public on Feb 6, 2007 & raised $25.2M at IPO.